import Link from "next/link";
import JsonLd from "@/components/JsonLd";
import ContactLink from "@/components/ContactLink";
import { buildPageMetadata } from "@/lib/seo";
import { faqPageJsonLd, isWhereToBuy } from "@/lib/faq-schema";

export const metadata = buildPageMetadata({
  path: "/compare/tb-500-vs-thymosin-beta-4",
  title: "TB-500 vs Thymosin Beta-4: Fragment vs Full Protein | Prof. Peptide",
  description:
    "TB-500 is the synthetic active fragment of the 43-aa Thymosin Beta-4 protein — not a rival compound. How they differ in structure, sourcing, and research.",
});

const rows = [
  ["What it is", "Naturally occurring 43-amino-acid protein found in nearly all mammalian cells", "Synthetic active fragment of Thymosin Beta-4 (the Tβ4 17-23 region) — the form most vendors sell"],
  ["Structure", "Full 43-aa peptide (encoded by the TMSB4X gene)", "Short synthetic fragment, usually supplied as an acetate salt"],
  ["Active region", "Contains the actin-binding / cell-migration active site (plus the rest of the protein)", "Retains that actin-binding active region — the part responsible for the repair activity"],
  ["Mechanism", "Actin sequestration → cell migration, angiogenesis, anti-inflammatory (M1→M2 macrophage shift), wound healing", "Same active region → the same core mechanism as the parent protein"],
  ["Sourcing", "Endogenous; full-length recombinant/synthetic protein is rarer and costlier as a research material", "Lab-synthesized; widely sold as a research peptide labeled “TB-500”"],
  ["Research context", "Named human trials exist (e.g. RegeneRx Phase 2 corneal / dry-eye programs)", "“TB-500” is largely the research-peptide and animal-model label; its evidence overlaps the Tβ4 literature"],
  ["What you actually receive", "Vials labeled “Thymosin Beta-4” may be the full protein, but the term is often used loosely", "Vials labeled “TB-500” are the synthetic fragment — check the COA and stated sequence"],
  ["FDA status", "Not FDA-approved", "Not FDA-approved"],
  ["Human evidence", "Limited — mostly preclinical, plus early-phase trials", "Limited — mostly preclinical / animal models"],
];

const faqs = [
  { q: "Is TB-500 the same as Thymosin Beta-4?", a: <>Not exactly &mdash; TB-500 is a synthetic fragment of the full Thymosin Beta-4 protein. The fragment retains the active region responsible for cell migration and wound healing but is shorter (and easier to synthesize) than the 43-amino-acid full protein. Most research literature uses the terms interchangeably, though strict pharmacology references distinguish them.</> },
  { q: "Is TB-500 just a fragment of TB4?", a: <>Yes. TB-500 corresponds to the active region of Thymosin Beta-4 (commonly described as the Tβ4 17-23 region) &mdash; the part that drives actin binding, cellular migration, and wound-healing activity. It is easier and cheaper to synthesize than the full 43-amino-acid protein, which is why it became the standard research-peptide form.</> },
  { q: "Which should I choose — TB-500 or Thymosin Beta-4?", a: <>For most research purposes they represent the same active molecule, so this isn&apos;t a which-is-better contest. In practice, nearly every vendor sells the TB-500 fragment (often as the acetate salt); full-length Thymosin Beta-4 is rarer and more expensive. Choose full-length only if your protocol specifically requires the complete protein &mdash; otherwise TB-500 is the default.</> },
  { q: "Is Thymosin Beta-4 FDA-approved?", a: <>No. Neither the full Thymosin Beta-4 protein nor the TB-500 fragment is FDA-approved. Thymosin Beta-4 reached Phase 2 human trials (notably RegeneRx&apos;s corneal and dry-eye programs), but no product has been approved, and most of the evidence base is preclinical. Both are sold research-use-only.</> },
  { q: "What do I actually receive when I order \"Thymosin Beta-4\" vs \"TB-500\"?", a: <>Usually the same synthetic fragment. Vials labeled &ldquo;TB-500&rdquo; are the fragment (frequently the acetate salt). &ldquo;Thymosin Beta-4&rdquo; can denote the full-length protein but is often used loosely for the same fragment. Check the Certificate of Analysis and the stated sequence/length to confirm exactly what you are getting.</> },
];

export default function TB500vsThymosinBeta4Page() {
  return (
    <>
      <JsonLd data={{"@context":"https://schema.org","@type":"Article","headline":"TB-500 vs Thymosin Beta-4: Fragment vs Full Protein","description":"TB-500 is the synthetic active fragment of the 43-amino-acid Thymosin Beta-4 protein — how the fragment and the full protein differ in structure, sourcing, and research.","url":"https://profpeptide.com/compare/tb-500-vs-thymosin-beta-4","publisher":{"@type":"Organization","name":"Prof. Peptide","url":"https://profpeptide.com"}}} />
      <JsonLd data={{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://profpeptide.com"},{"@type":"ListItem","position":2,"name":"Comparisons","item":"https://profpeptide.com/compare"},{"@type":"ListItem","position":3,"name":"TB-500 vs Thymosin Beta-4: Fragment vs Full Protein"}]}} />
      <JsonLd data={faqPageJsonLd(faqs, isWhereToBuy)} />
    <div className="section max-w-4xl">
      <Link href="/compare" className="text-sm text-[#0891b2] hover:underline mb-6 inline-block">&larr; Back to Comparisons</Link>
      <h1 className="text-3xl font-bold text-[#1e2d3d] dark:text-slate-100 mb-3">TB-500 vs Thymosin Beta-4 &mdash; Fragment vs Full Protein</h1>
      <p className="text-lg text-gray-500 dark:text-slate-400 leading-relaxed mb-8 max-w-2xl"><Link href="/peptides/tb-500" className="text-[#0891b2] hover:underline">TB-500</Link> and Thymosin Beta-4 are searched as if they&apos;re two compounds to choose between &mdash; but they&apos;re not rivals. TB-500 is the synthetic active fragment of the naturally occurring Thymosin Beta-4 (Tβ4) protein. This page explains the real relationship, the genuine differences, and what it means in practice.</p>

      <div className="bg-[#0891b2]/10 border border-[#0891b2]/20 rounded-xl p-5 mb-8">
        <p className="text-lg text-[#1e2d3d] dark:text-slate-100 mb-2"><strong>Thymosin Beta-4 (Tβ4):</strong> the full, naturally occurring 43-amino-acid protein &mdash; the parent molecule.</p>
        <p className="text-lg text-[#1e2d3d] dark:text-slate-100 mb-2"><strong>TB-500:</strong> the synthetic active fragment of Tβ4 &mdash; shorter, easier to make, and the form nearly all vendors actually sell.</p>
        <p className="text-lg text-[#1e2d3d] dark:text-slate-100"><strong>Bottom line up front:</strong> same active molecule family, not a &ldquo;which is better&rdquo; contest &mdash; the practical differences are length, sourcing, and cost.</p>
      </div>

      <div className="mb-8 p-5 border border-[#0891b2]/20 bg-[#0891b2]/10 rounded-xl">
        <h2 className="text-lg font-semibold text-[#1e2d3d] dark:text-slate-100 mb-3">Why people think these are two different compounds</h2>
        <p className="text-lg text-gray-600 dark:text-slate-300 leading-relaxed mb-3">
          Vendors and forums use &ldquo;TB-500&rdquo; and &ldquo;Thymosin Beta-4&rdquo; as if they were competing products, so people assume they must pick one. In reality, Thymosin Beta-4 is a 43-amino-acid protein your cells already make, and TB-500 is a lab-synthesized fragment of it &mdash; specifically the active region (often described as the Tβ4 17-23 region) that carries the actin-binding and cell-migration activity.
        </p>
        <p className="text-lg text-gray-600 dark:text-slate-300 leading-relaxed mb-3">
          The fragment became the standard research-peptide form for a practical reason: it is far easier and cheaper to synthesize than the full-length protein while retaining the part responsible for the repair effects. So most material sold as &ldquo;TB-500&rdquo; &mdash; and much of what is loosely labeled &ldquo;Thymosin Beta-4&rdquo; &mdash; is the same synthetic fragment, commonly supplied as an acetate salt.
        </p>
        <p className="text-lg text-gray-600 dark:text-slate-300 leading-relaxed">
          Because they share the same active region, they share the same core mechanism. Framing them as a head-to-head efficacy contest is misleading; the honest comparison is fragment vs full protein, and what that means for sourcing, cost, and what you actually receive.
        </p>
      </div>

      <div className="overflow-x-auto mb-8">
        <table className="w-full text-sm border-collapse">
          <thead>
            <tr className="bg-gray-50 dark:bg-[#1e293b]">
              <th className="text-left px-4 py-3 font-semibold text-gray-400 dark:text-slate-500 text-xs uppercase tracking-wider border-b border-gray-100 dark:border-slate-700 w-1/4"></th>
              <th className="text-left px-4 py-3 font-semibold text-[#0891b2] text-xs uppercase tracking-wider border-b border-gray-100 dark:border-slate-700 w-[37.5%]">Thymosin Beta-4 (full protein)</th>
              <th className="text-left px-4 py-3 font-semibold text-[#0891b2] text-xs uppercase tracking-wider border-b border-gray-100 dark:border-slate-700 w-[37.5%]">TB-500 (fragment)</th>
            </tr>
          </thead>
          <tbody>
            {rows.map(([label, a, b], i) => (
              <tr key={i} className={i % 2 === 0 ? "bg-white dark:bg-[#0f172a]" : "bg-gray-50/50 dark:bg-slate-800/50"}>
                <td className="px-4 py-3 font-medium text-[#1e2d3d] dark:text-slate-100 border-b border-gray-100 dark:border-slate-700">{label}</td>
                <td className="px-4 py-3 text-gray-600 dark:text-slate-300 border-b border-gray-100 dark:border-slate-700">{a}</td>
                <td className="px-4 py-3 text-gray-600 dark:text-slate-300 border-b border-gray-100 dark:border-slate-700">{b}</td>
              </tr>
            ))}
          </tbody>
        </table>
      </div>

      <div className="mb-8">
        <h2 className="text-lg font-semibold text-[#1e2d3d] dark:text-slate-100 mb-2">Which one is right for you?</h2>
        <p className="text-lg text-gray-500 dark:text-slate-400 leading-relaxed mb-4">
          Both are research-use-only and neither is FDA-approved. Since they share the same active region, the choice is practical rather than an efficacy question.
        </p>
        <div className="space-y-4">
          <div className="border border-gray-100 dark:border-slate-700 rounded-xl p-5">
            <h3 className="text-lg font-semibold text-[#1e2d3d] dark:text-slate-100 mb-2">Most research use — the fragment (TB-500)</h3>
            <p className="text-lg text-gray-600 dark:text-slate-300 leading-relaxed">
              For the overwhelming majority of tissue-repair research questions, TB-500 is the default. It carries the active actin-binding region, it is what nearly every vendor stocks, and it is cheaper and more consistently available than the full-length protein. If a protocol just calls for &ldquo;Thymosin Beta-4 activity,&rdquo; the fragment is what is typically used.
            </p>
          </div>
          <div className="border border-gray-100 dark:border-slate-700 rounded-xl p-5">
            <h3 className="text-lg font-semibold text-[#1e2d3d] dark:text-slate-100 mb-2">When the full-length protein specifically matters</h3>
            <p className="text-lg text-gray-600 dark:text-slate-300 leading-relaxed">
              Some research questions target properties of the complete 43-amino-acid protein (for example, regions outside the core active fragment, or work aligned with the named Thymosin Beta-4 clinical programs). In those cases full-length Tβ4 is the correct material &mdash; expect it to be rarer and more expensive, and verify the sequence/length on the Certificate of Analysis.
            </p>
          </div>
          <div className="border border-gray-100 dark:border-slate-700 rounded-xl p-5">
            <h3 className="text-lg font-semibold text-[#1e2d3d] dark:text-slate-100 mb-2">Verify what you are actually buying</h3>
            <p className="text-lg text-gray-600 dark:text-slate-300 leading-relaxed">
              Because the labels are used loosely, the most important step is checking the COA. A vial labeled &ldquo;Thymosin Beta-4&rdquo; is not guaranteed to be the full protein, and &ldquo;TB-500&rdquo; is the fragment. Confirm the stated amino-acid sequence/length and salt form so the material matches your protocol.
            </p>
          </div>
        </div>
      </div>

      <div className="border border-gray-100 dark:border-slate-700 rounded-xl p-5 mb-8">
        <h2 className="text-xl font-bold text-[#1e2d3d] dark:text-slate-100 mb-2">Bottom Line</h2>
        <p className="text-lg text-gray-600 dark:text-slate-300"><Link href="/peptides/tb-500" className="text-[#0891b2] hover:underline">TB-500</Link> and Thymosin Beta-4 are not competing compounds &mdash; TB-500 is the synthetic active fragment of the full 43-amino-acid Thymosin Beta-4 protein, and it is the form nearly all vendors sell. They share the same active region and the same core mechanism, so this is a fragment-vs-full-protein distinction, not a which-is-better contest. Most research uses the fragment; full-length Tβ4 is reserved for questions that specifically require the complete protein. Neither is FDA-approved, the evidence base is largely preclinical, and both are sold research-use-only &mdash; always verify the sequence on the Certificate of Analysis. Commonly stacked with <Link href="/peptides/bpc-157" className="text-[#0891b2] hover:underline">BPC-157</Link> in the <Link href="/peptides/wolverine-stack" className="text-[#0891b2] hover:underline">Wolverine Stack</Link>.</p>
      </div>

      <div className="mb-8">
        <h2 className="text-lg font-semibold text-[#1e2d3d] dark:text-slate-100 mb-4">FAQ</h2>
        <div className="space-y-4">
          {faqs.map((f, i) => (
            <div key={i}>
              <h3 className="text-lg font-semibold text-[#1e2d3d] dark:text-slate-100 mb-1">{f.q}</h3>
              <p className="text-lg text-gray-600 dark:text-slate-300 leading-relaxed">{f.a}</p>
            </div>
          ))}
        </div>
      </div>

      <div className="mb-8">
        <h2 className="text-lg font-semibold text-[#1e2d3d] dark:text-slate-100 mb-3">References</h2>
        <ol className="list-decimal list-inside space-y-2">
          <li className="text-sm text-gray-600 dark:text-slate-300 leading-relaxed">
            Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51.{" "}
            <a href="https://pubmed.ncbi.nlm.nih.gov/22074294/" target="_blank" rel="noopener noreferrer" className="text-[#0891b2] hover:underline break-words">https://pubmed.ncbi.nlm.nih.gov/22074294/</a>
          </li>
          <li className="text-sm text-gray-600 dark:text-slate-300 leading-relaxed">
            Malinda KM, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368.{" "}
            <a href="https://pubmed.ncbi.nlm.nih.gov/10469335/" target="_blank" rel="noopener noreferrer" className="text-[#0891b2] hover:underline break-words">https://pubmed.ncbi.nlm.nih.gov/10469335/</a>
          </li>
          <li className="text-sm text-gray-600 dark:text-slate-300 leading-relaxed">
            Smart N, Risebro CA, Melville AA, et al. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007;445(7124):177-182.{" "}
            <a href="https://pubmed.ncbi.nlm.nih.gov/17108969/" target="_blank" rel="noopener noreferrer" className="text-[#0891b2] hover:underline break-words">https://pubmed.ncbi.nlm.nih.gov/17108969/</a>
          </li>
          <li className="text-sm text-gray-600 dark:text-slate-300 leading-relaxed">
            Sosne G, Qiu P, Kurpakus-Wheater M. Thymosin beta4 and corneal wound healing: visions of the future. Ann N Y Acad Sci. 2010;1194:190-198.{" "}
            <a href="https://pubmed.ncbi.nlm.nih.gov/20536468/" target="_blank" rel="noopener noreferrer" className="text-[#0891b2] hover:underline break-words">https://pubmed.ncbi.nlm.nih.gov/20536468/</a>
          </li>
          <li className="text-sm text-gray-600 dark:text-slate-300 leading-relaxed">
            Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. 2025 (review; notes TB-500/Tβ4 human clinical evidence remains limited).{" "}
            <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12753158/" target="_blank" rel="noopener noreferrer" className="text-[#0891b2] hover:underline break-words">https://pmc.ncbi.nlm.nih.gov/articles/PMC12753158/</a>
          </li>
        </ol>
      </div>

      <div className="flex flex-wrap gap-3 mb-8">
        <Link href="/peptides/tb-500" className="btn-primary text-sm">TB-500 Profile</Link>
        <Link href="/compare/bpc-157-vs-tb-500" className="btn-outline text-sm">BPC-157 vs TB-500</Link>
        <Link href="/peptides/wolverine-stack" className="btn-outline text-sm">Wolverine Stack</Link>
      </div>

      <p className="text-xs text-gray-400 dark:text-slate-500 leading-relaxed">For educational and research purposes only. Not medical advice. Not for human use.</p>
    <ContactLink pageName="TB-500 vs Thymosin Beta-4 — Fragment vs Full Protein" pagePath="/compare/tb-500-vs-thymosin-beta-4" />
    </div>
    </>
  );
}
